Physician profile
Aaron T Billowitz
NPI 1659465532
$438.91
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $27.21.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $141.76 | 2019 | |
| Sunovion Pharmaceuticals INC. | $81.56 | 2019 | |
| Neurocrine Biosciences, INC. | $40.27 | 2019-2020 | |
| Allergan, INC. | $39.63 | 2019 | |
| Shire North American Group INC | $34.25 | 2019 | |
| Lundbeck LLC | $25.87 | 2019-2020 | |
| Validus Pharmaceuticals LLC | $18.31 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $16.63 | 2019 | |
| Bausch Health US, LLC | $15.01 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.61 | 2019 | |
| Adlon Therapeutics L.P. | $12.01 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Billowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.